Drug Combinations, Repurposing, and Differentiation

• 4453 · PDF Ataxia telangiectasia and Rad3 related kinase inhibitors and gemcitabine induce synergistic killing of uterine leiomyosarcoma cells Megan Doherty, Minnie Malik, Montanna Macias-Young, Adora Jacobs, Yuka Otsuka, William H. Catherino
• 4454 · PDF AI-driven discovery of an IRP2-EGFR dual-targeting strategy reveals synergistic antitumor efficacy in colorectal cancer Soseul Won, Jieon Hwang, Sejeong Park, Sunkyu Kim, Sanghoon Lee, Areum Park, Hyuk Lee, Joong-Bae Ahn, Jaewoo Kang, Sang Joon Shin
• 4455 Efficacy of Tumor Treating Fields (TTFields) together with standard chemotherapy and PD-L1 blockage in preclinical models of small cell lung carcinoma Rotem Engelman, Lina Somri-Gannam, Talya Borkum, Roni Blatt, Daria Gerasimova, Shay Cahal, Catherine Tempel Brami, Mai Shai, Yiftah Barsheshet, Eyal Dor-On, Itai Tzchori, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
• 4456 Tumor Treating Fields (TTFields) potentiate antitumor and immune responses to standard immunochemotherapy in non-small cell lung cancer models Boris Brant, Yiftah Barsheshet, Tali Voloshin, Tal Kan, Tharwat Haj Khalil, Simona Zisman-Rozen, Lilach Koren, Avital Vorontsov, Bella Koltun, Cfir David, Anat Klein-Goldberg, Efrat Zemer-Tov, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
• 4457 · PDF A novel CerS2 activator, DH20931, synergizes with doxorubicin to overcome therapeutic resistance in breast cancer Hissah Alatawi, Haritha H. Nair, Lingbao Ai, Abhisheak Sharma, Christopher Vulpe, Arun K. Sharma, Coy D. Heldermon, Satya Narayan
• 4458 · PDF Enhancing the antitumor efficacy using a combination of FGFR4 inhibitor(H3B-6527) and oxaliplatin in gastric cancer Nadeem Bhat, Mohammed Soutto, Ahmed Gomaa, Shoumin Zhu, Selma Maacha, Marwah Al-Mathkour, Melanie Genoula, Oliver McDonald, Wael El-Rifai
• 4459 · PDF Repurposed FDA-approved agents for hepatic artery infusion in colorectal liver metastases Manasa Ravi, Colin M. Court, April Risinger
• 4460 · PDF Drug repurposing in Nectin-4-positive epithelial ovarian cancer Xiaoyan Zhong, Runying Long, Ruiqian Zhang, Ling Shan Hung, Can Cui, Chen Bao, Kui Liu, Cho Wing Li, Haonan Lu, Kar Loen Chan
• 4461 · PDF Nebivolol exhibits cell growth inhibition in drug-resistant HR+/HER2- breast cancer and anti-tumoral synergism with abemaciclib in vitro Chia-Ling Wu, Meghana Trivedi, Shivaani Suresh Kanna
• 4462 Nebivolol inhibits cell growth, inhibits autophagic flux, and enhances growth inhibition in combination with bicalutamide in prostate cancer cells Swarnil Mandal, Chia-Ling Wu, Shivaani S. Kanna, Wangjia Cao, Meghana V. Trivedi
• 4463 Repurposing the anti-dementia drug memantine, (a dualalpha7-nAChR NMDAR antagonist) as an anti-cancer agent in human squamous cell lung cancer Javan Christian, Sarah L. Miles, Kritsa L. Denning, Kushal J. Modi, Reagan S. Light, Piyali Dasgupta, Yi Charlie Chen
• 4464 · PDF Repurposing nebivolol with CPI-613 for triple-negative breast cancer: Linking in-vitro synergy to in-vivo exposure Mikayla Skillman, Airong Li, Junhyoung Park, Amir Mohammad-Gholizadeh, Fatima Dagher, Meghana Trivedi, Benny Kaiparettu, Diana S-L Chow
• 4465 Miconazole induces cell cycle arrest and apoptosis in prostate cancer cells via a p53-mediated pathway: A Drug repurposing strategy Eswara Naga Hanuma Kumar Ghali, Lindsey Shim, Rahul Tiwari, Rajasekhar Baru, Anupam Dhasmana, Chang Ryan Jisoo, Sung Yun Jung, Vivek Kumar Kashyap, Neeraj Chauhan, Subhash C. Chauhan, Murali M. Yallapu
• 4466 Clinical-grade CK2 inhibitor CX-4945 synergistically enhances venetoclax-mediated antileukemic activity in preclinical acute myeloid leukemia models Upendarrao Golla, Muhammad Danial, Rajesh Rajaiah, Marudhu Pandiyan Shanmugam, Koby Duke, Katherine Mercer, Yi Qiu, Sinisa Dovat, Yasin Uzun, Hong Zheng, Suming Huang, Chandrika G. Behura
• 4467 · PDF Synergistic antileukemic activity of JAK inhibition combined with cytarabine in acute megakaryoblastic leukemia Akira Shimada, Shiho Aoki, Hiroko Hayakawa, Erico Jimbo, Narumi Omika, Kaito Furuya, Hideya Asai, Hiroki Yoshinari, Hitomi Niijima, Yuta Kawahara, Kentaro Ushijima, Masakazu Mimaki, Mitsuteru Hiwatari
• 4468 · PDF WNK1 inhibition induces AML differentiation via ERK-CEBPbeta signaling Jordan D. Cress, Emily Katoni, Parameswaran Ramakrishnan
• 4469 · PDF FACT Complex - A gatekeeper of differentiation in AML Soumya Sharma, Sagarajit Mohanty, Stefan R. Sweha, Kazuya Fukasawa, Jieun Jeong, Katerina V. Gurova, Hans-Guido Wendel
• 4470 Combination of NAMPT inhibitors plus pyrimidine analog antimetabolites floxuridine and 5-FU impair rhabdomyosarcoma proliferation and survival Jamie Gudyka, Choh Yeung, Senna Munnikhuysen, Christina M. Robinson, Amy James, Xiaohu Zhang, David Holland, Michele Ceribelli, Simone Difilippantonio, Craig J. Thomas, Christine M. Heske
• 4471 Synergistic metabolic inhibition with 2-DG and metformin loaded electrospun scaffolds disrupts glioblastoma redox balance and glycolytic output Bryce William Jewett
• 4472 Combination of medroxyprogesterone acetate (MPA) and a WEE1 or ATR inhibitor enhances anti-tumor activity of estrogen receptor-positive endometrial cancer cells Yuki Takemoto, Yasuto Kinose, Li Han, Mai Koizumi, Yan Wang, Kanako Kasuya, Aasa Shimizu, Erika Nakatsuka, Mahiru Kawano, Kenjiro Sawada, Michiko Kodama
• 4473 · PDF Advancing new rational drug combinations to treat mutant KRAS-driven pancreatic adenocarcinoma Brajendra K. Tripathi, Sophia M. Shahin, Elise Van Meter, Marian E. Durkin, Xiaolan Qian, Ross Lake, James H. Doroshow, Dunrui Wang, Douglas R. Lowy
• 4474 Cannabidiol enhances etoposide efficacy in non-small cell lung cancer by engaging a p53-mTOR-TFEB lysosomal death program Youngsic Jeon, Hyukjoon Kwon, Young Nyun Park, Taejung Kim, Young-Joo Kim
• 4475 · PDF Neuroendocrine-like dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axis Alessandra Morselli, Chiara Miroglio, William Kothalawala, Donatella Romaniello, Idan Lahat, Paola Cecchi, Davide Zilio, Michelangelo Fiorentino, Andrea Ardizzoni, Yosef Yarden, Yaara Oren, Balazs Gyorffy, Mattia Lauriola
• 4476 Repurposing PARP inhibitors in molecularly defined subgroups of peritoneal metastatic colorectal cancer (pmCRC): Preclinical analysis of patient-derived xenograft (PDX) models Mathias Dahlmann, Beate Rau, Safak Gül-Klein, Bernadette Brzezicha, Marlen Keil, Antje Wengner, Jens Hoffmann, Sebastian Stintzing, Ulrike S. Stein, Wolfgang Walther, Loredana Vecchione
• 4478 · PDF Synergistic antitumor activity of tumor-treating fields and multiselect-RAS (ON) inhibitor RMC-6236 in pancreatic ductal adenocarcinoma Ishita Saha, Santanu Bhattacharya, Debabrata Mukhopadhyay, Hani M. Babiker

在完整检索应用中浏览本分会场 →